Epigenetic silencing of SALL2 confers tamoxifen resistance in breast cancer

Resistance to tamoxifen is a clinically major challenge in breast cancer treatment. Although downregulation of estrogen receptor‐alpha (ERα) is the dominant mechanism of tamoxifen resistance, the reason for ERα decrease during tamoxifen therapy remains elusive. Herein, we reported that Spalt‐like tr...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:EMBO Mol Med
Egile Nagusiak: Ye, Liping, Lin, Chuyong, Wang, Xi, Li, Qiji, Li, Yue, Wang, Meng, Zhao, Zekun, Wu, Xianqiu, Shi, Dongni, Xiao, Yunyun, Ren, Liangliang, Jian, Yunting, Yang, Meisongzhu, Ou, Ruizhang, Deng, Guangzheng, Ouyang, Ying, Chen, Xiangfu, Li, Jun, Song, Libing
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: John Wiley and Sons Inc. 2019
Gaiak:
Articles
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6895605/
https://ncbi.nlm.nih.gov/pubmed/31657150
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.15252/emmm.201910638
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak